<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980174</url>
  </required_header>
  <id_info>
    <org_study_id>20080098</org_study_id>
    <nct_id>NCT00980174</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab Versus Placebo in Males With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how effective and safe denosumab is in a population of
      males with low bone mass at risk of fracture. The primary clinical hypothesis is that in men
      with low bone mineral density, the mean percent change in lumbar spine bone mineral density
      at 12 months in subjects receiving denosumab will be greater than in subjects receiving
      placebo. Denosumab is a fully human monoclonal antibody with a high affinity for Receptor
      Activator of Nuclear Factor (RANK) Ligand that can bind and neutralize the activity of human
      RANK Ligand similar to the action of endogenous osteoprotegerin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>From Baseline to 12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>From Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>From Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanter Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>From Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>From Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15</measure>
    <time_frame>From Baseline to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Low Bone Mass</condition>
  <condition>Low Bone Mineral Density</condition>
  <condition>Males With Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 mg denosumab</intervention_name>
    <description>60 mg denosumab (SC injection every 6 months)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>denosumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for denosumab (SC injection every 6 months)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bone Mineral Density (BMD) values (g/cm2) assessed by the local site at either the
             lumbar spine OR femoral neck that occur within the ranges specified in the protocol OR
             For subjects with a history of a major osteoporotic fracture (clinical vertebral, hip,
             humerus and distal radius fractures) occurring more than 6 months prior to screening,
             BMD values (g/cm2) assessed by the local site, at either the lumbar spine OR femoral
             neck that occur within the ranges specified in the protocol.

          -  At least 2 lumbar vertebrae, at least 1 hip and at least one forearm must be evaluable
             by Dual X ray Absorptiometry (DXA).

          -  Ambulatory males 30 to 85 years of age inclusive at the start of screening.

          -  Provide the appropriate written informed consent before any study specific procedure.

        Exclusion Criteria:

          -  BMD values (g/cm2) as specified in the protocol in subjects with or without a history
             of major osteoporotic fractures, based on the particular scanner that is used.

          -  Any disorder that compromises the ability of the subject to give written informed
             consent and/or to comply with study procedures.

          -  Any severe or more than 1 moderate vertebral fractures on screening spinal x ray

          -  Any vertebral fracture diagnosed within the 6 months prior to screening

          -  Any clinical fracture within the last 6 months prior to screening

          -  For males with a partner of childbearing potential: Subject refuses to use 2 highly
             effective methods of contraception for the duration of the study and for 10 months
             after the last dose of study medication.

          -  For males with a partner who is pregnant: Subject refuses to use a condom for the
             duration of the study and for 10 months after the last dose of study medication.

          -  Previous participation in clinical trials with denosumab or administration of
             commercial denosumab.

          -  Currently enrolled in or has not yet completed at least 1 month since ending other
             investigational device or drug trial(s), or subject is receiving other investigational
             agent(s).

          -  Vitamin D deficiency [25(OH) vitamin D level &lt; 20 ng/mL (&lt; 49.9 nmol/L)]. Vitamin D
             replenishment will be permitted and subjects may be re-screened; see Section 7.

          -  Hyper- or hypothyroidism; however, stable subjects, in the investigator's opinion, on
             thyroid hormone replacement therapy are allowed.

          -  Hyper- or hypoparathyroidism. Intact parathyroid hormone (iPTH) values outside of the
             reference range as determined by the central laboratory

          -  Elevated transaminases. Serum aspartate aminotransferase; serum glutamate-oxaloacetic
             transaminase &gt; 2.5 x upper limit of normal. Serum alanine aminotransferase; serum
             glutamate pyruvate transaminase &gt; 2.5 x upper limit of normal (both as determined by
             the central laboratory).

          -  Significantly impaired renal function as determined by a derived glomerular filtration
             rate (using the Modification of Diet in Renal Disease formula) of less than or equal
             to 30 mL/min/1.73 m2 calculated by the central laboratory.

          -  Hypo- or hypercalcemia based on the central laboratory reference ranges for
             albumin-adjusted serum calcium.

          -  Known to have tested positive for human immunodeficiency virus, hepatitis C virus,
             hepatitis B surface antigen or cirrhosis of the liver.

          -  Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma)
             within the last 5 years.

          -  Any metabolic bone disease, eg osteomalacia, osteogenesis imperfecta, rheumatoid
             arthritis, Paget's disease, Cushing's disease or, hyperprolactinemia which may
             interfere with the interpretation of the findings OR evidence of malabsorption
             syndromes which might interfere with absorption of vitamin D.

          -  Received any solid organ or bone marrow transplant or is on chronic immunosuppression
             for any reason.

          -  Any laboratory abnormality, which in the opinion of the investigator or Amgen, will
             prevent the subject from completing the study or interfere with the interpretation of
             the study results.

          -  Administration of intravenous bisphosphonate, or fluoride (except for dental
             treatment) or strontium ranelate.

          -  Oral bisphosphonate treatment:

          -  greater than or equal to 3 months cumulatively in the past 2 years, OR

          -  greater than or equal to 1 month in the past year, OR

          -  Any use during the 3-month period prior to randomization

          -  Administration of any of the following treatments 3 months prior to screening:

          -  Anabolic steroids or testosterone

          -  Glucocorticosteroids (greater than or equal to 5 mg prednisone equivalent per day for
             more than 10 days or a total cumulative dose of greater than or equal to 50 mg)

          -  Calcitonin

          -  Calcitriol or vitamin D derivatives [vitamin D contained in supplements or
             multivitamins is allowed]

          -  Other bone active drugs including anti-convulsives (except benzodiazepines) and
             heparin

          -  Chronic systemic ketoconazole, adrenocorticotrophic hormone (ACTH), cinacalcet,
             aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone
             agonists.

          -  Androgen deprivation therapy

          -  Known sensitivity to mammalian cell derived drug products.

          -  Known intolerance to calcium or vitamin D supplements.

          -  Height, weight or girth which may preclude accurate DXA measurements.

          -  Bilateral hip replacements

          -  Any physical or psychiatric disorder which, in the opinion of the investigator or
             Amgen, will prevent the subject from completing the study or interfere with the
             interpretation of the study results.

          -  Evidence of alcohol or substance-abuse within the last 12 months which the
             investigator believes would interfere with understanding of or completion of the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>October 31, 2012</results_first_submitted>
  <results_first_submitted_qc>October 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2012</results_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>men</keyword>
  <keyword>male</keyword>
  <keyword>denosumab</keyword>
  <keyword>BMD</keyword>
  <keyword>lumbar spine</keyword>
  <keyword>ADAMO</keyword>
  <keyword>The ADAMO Trial</keyword>
  <keyword>male osteoporosis</keyword>
  <keyword>osteoporosis in men</keyword>
  <keyword>males with low bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" spread="9.1"/>
                    <measurement group_id="B2" value="64.9" spread="10.5"/>
                    <measurement group_id="B3" value="65.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>From Baseline to 12 Months</time_frame>
        <population>Subjects with baseline and at least one post baseline measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <population>Subjects with baseline and at least one post baseline measurements</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.1" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted by level of baseline bone mineral density T-score</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.0</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
            <estimate_desc>Denosumab - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>From Baseline to 12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.1" upper_limit="0.7"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons by Hochberg method</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted by level of baseline bone mineral density T-score</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Denosumab - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>From Baseline to 12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.6" upper_limit="0.6"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.5" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons by Hochberg method</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted by level of baseline bone mineral density T-score</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Denosumab - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trochanter Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>From Baseline to 12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Trochanter Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.2" upper_limit="1.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.5" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons by Hochberg method</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted by level of baseline bone mineral density T-score</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Denosumab - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>From Baseline to 12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.8" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons by Hochberg method</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted by level of baseline bone mineral density T-score</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Denosumab - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15</title>
        <time_frame>From Baseline to Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15</title>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" lower_limit="-20" upper_limit="16"/>
                    <measurement group_id="O2" value="-81" lower_limit="-86" upper_limit="-75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons by Hochberg method</p_value_desc>
            <method>Van Elteren Rank Test</method>
            <method_desc>Adjusted by level of baseline bone mineral density T-score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Skull malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basilar artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

